SAN FRANCISCO ― Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it ...

Nov 5 (Reuters) - Pfizer (PFE.N), opens new tab is preparing to sweeten its offer again for Metsera (MTSR.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...

Pfizer (NYSE:PFE) is preparing to release its quarterly earnings on Tuesday, 2025-11-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Pfizer ...

The pharma giant may be heading for a new era of growth. In later stages of the pandemic, sales of coronavirus products flagged. To add to this bad news, investors focused on upcoming patent ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...